{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T01:15:34Z","timestamp":1755998134264},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2016,12,22]],"date-time":"2016-12-22T00:00:00Z","timestamp":1482364800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s10157-016-1366-5","type":"journal-article","created":{"date-parts":[[2016,12,22]],"date-time":"2016-12-22T06:14:15Z","timestamp":1482387255000},"page":"4-8","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Research on kidney and mineral metabolism in Japan: past, present, and future"],"prefix":"10.1007","volume":"21","author":[{"given":"Masahide","family":"Mizobuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiko","family":"Koiwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Kinugasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadao","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,22]]},"reference":[{"key":"1366_CR1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/230228a0","volume":"230","author":"D Lawson","year":"1971","unstructured":"Lawson D, Fraser D, Kodicek E, et al. Identification of 1,25-dihydroxychelecalciferol, a new kidney hormone controlling calcium metabolism. Nature. 1971;230:228\u201330.","journal-title":"Nature"},{"key":"1366_CR2","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1172\/JCI111639","volume":"74","author":"E Slatopolsky","year":"1984","unstructured":"Slatopolsky E, Weerts C, Thielan J, et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1, 25-dihydroxy-cholecalciferol in uremic patients. J Clin Investig. 1984;74:2136\u201343.","journal-title":"J Clin Investig"},{"issue":"11","key":"1366_CR3","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69(11):1945\u201353.","journal-title":"Kidney Int"},{"issue":"6","key":"1366_CR4","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1744-9987.2008.00648.x","volume":"12","author":"Guideline Working Group JSDT","year":"2008","unstructured":"Guideline Working Group JSDT. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial. 2008;12(6):514\u201325.","journal-title":"Ther Apher Dial"},{"issue":"20","key":"1366_CR5","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1021\/bi00717a006","volume":"13","author":"JE Zerwekh","year":"1974","unstructured":"Zerwekh JE, Brumbaugh PF, Haussler DH, Cork DJ, Haussler MR. 1Alpha-hydroxyvitamin D3. An analog of vitamin D which apparently acts by metabolism to 1alpha, 25-dihydroxyvitamin D3. Biochemistry. 1974;13(20):4097\u2013102.","journal-title":"Biochemistry"},{"key":"1366_CR6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000420167","volume":"91","author":"Y Nishii","year":"1991","unstructured":"Nishii Y, Abe J, Mori T, et al. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. Contrib Nephrol. 1991;91:123\u20138.","journal-title":"Contrib Nephrol"},{"issue":"2","key":"1366_CR7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/ajkd.1998.v32.pm9708607","volume":"32","author":"T Akiba","year":"1998","unstructured":"Akiba T, Marumo F, Owada A, et al. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis. 1998;32(2):238\u201346.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"1366_CR8","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1172\/JCI116720","volume":"92","author":"N Fukuda","year":"1993","unstructured":"Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Investig. 1993;92(3):1436\u201343.","journal-title":"J Clin Investig"},{"issue":"1","key":"1366_CR9","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ki.1997.41","volume":"51","author":"J Gogusev","year":"1997","unstructured":"Gogusev J, Duchambon P, Hory B, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 1997;51(1):328\u201336.","journal-title":"Kidney Int"},{"issue":"Suppl 3","key":"1366_CR10","first-page":"iii42","volume":"18","author":"K Shiizaki","year":"2003","unstructured":"Shiizaki K, Negi S, Mizobuchi M, et al. Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients. Nephrol Dial Transplant. 2003;18(Suppl 3):iii42\u20136.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"1366_CR11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ndt\/gfm534","volume":"23","author":"M Fukagawa","year":"2008","unstructured":"Fukagawa M, Yumita S, Akizawa T, et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant. 2008;23(1):328\u201335.","journal-title":"Nephrol Dial Transplant"},{"key":"1366_CR12","doi-asserted-by":"crossref","unstructured":"Fukagawa M, Yokoyama K, Shigematsu T, et al. A phase 3. Multicenter, rondomised, double-blind, placebocontrolled, par-allel-group study to evaluate the efficacy and safety of etelcal-cetide (ONO-5163\/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol Dial Transplant. 2016 (in press).","DOI":"10.1093\/ndt\/gfw190.18"},{"issue":"3","key":"1366_CR13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/1744-9987.12058","volume":"17","author":"M Fukagawa","year":"2013","unstructured":"Fukagawa M, Yokoyama K, Koiwa F, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial. 2013;17(3):247\u201388.","journal-title":"Ther Apher Dial"},{"issue":"26","key":"1366_CR14","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"ET Investigators","year":"2012","unstructured":"Investigators ET, Chertow GM, Block GA, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482\u201394.","journal-title":"N Engl J Med"},{"key":"1366_CR15","doi-asserted-by":"crossref","first-page":"19612","DOI":"10.1038\/srep19612","volume":"6","author":"T Akizawa","year":"2016","unstructured":"Akizawa T, Kurita N, Mizobuchi M, et al. PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Sci Rep. 2016;6:19612.","journal-title":"Sci Rep"},{"issue":"8","key":"1366_CR16","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208\u201318.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"1366_CR17","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","volume":"70","author":"K Kalantar-Zadeh","year":"2006","unstructured":"Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70(4):771\u201380.","journal-title":"Kidney Int"},{"issue":"2","key":"1366_CR18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/1744-9987.12030","volume":"17","author":"M Taniguchi","year":"2013","unstructured":"Taniguchi M, Fukagawa M, Fujii N, et al. Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients. Ther Apher Dial. 2013;17(2):221\u20138.","journal-title":"Ther Apher Dial"},{"key":"1366_CR19","doi-asserted-by":"crossref","unstructured":"Akizawa T, Origasa H, Kameoka C, et al. Bixalomer in hyperphosphatemic patients with chronic kidney disease not on dialysis: phase 3 randomized trial. Ther Apher Dial. 2016 (in press).","DOI":"10.1111\/1744-9987.12461"},{"issue":"5","key":"1366_CR20","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1159\/000344008","volume":"36","author":"K Yokoyama","year":"2012","unstructured":"Yokoyama K, Hirakata H, Akiba T, Sawada K, Kumagai Y. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol. 2012;36(5):478\u201387.","journal-title":"Am J Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-016-1366-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-016-1366-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-016-1366-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T02:31:50Z","timestamp":1498357910000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-016-1366-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,22]]},"references-count":20,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["1366"],"URL":"https:\/\/doi.org\/10.1007\/s10157-016-1366-5","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,22]]}}}